Search Bar & Filters
Found 59 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying ASTX030, a combination of azacitidine and cedazuridine, alone or with venetoclax in people with myeloid neoplasms including myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML, and acute myeloid leukemia AML. This multi-phase study includes phases 1 through 3 for monotherapy and phases 1 and 2 for combination therapy, aiming to evaluate the safety, pharmacokinetics, and effectiveness of these treatments over approximately 8 years. Participants receive various treatments depending on the study phase and arm. Treatments include oral doses of azacitidine, cedazuridine, ASTX030, subcutaneous azacitidine, and venetoclax in different sequences and cycles, typically lasting 28 days each. Some phases involve dose escalation and expansion stages, while others compare oral and subcutaneous forms or combine ASTX030 with venetoclax. Participants in certain arms may cross over to other treatments later in the study. During the study, participants undergo regular assessments including blood tests to measure drug levels, DNA methylation, and response rates such as complete remission. Researchers track adverse events, survival outcomes, transfusion independence, and pharmacokinetics up to 36 months or longer depending on the phase. Safety monitoring includes up to 24 months for some arms. The study involves scheduled visits for dosing and evaluations, with ongoing data collection to understand treatment effects and safety.
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of chemotherapy treatments in adults diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN. This observational study aims to provide comparative data to the ELZONRIS registry study by reviewing real-world outcomes of patients treated with various chemotherapy regimens as their first-line therapy since May 2016. Participants have received chemotherapy regimens similar to those used for acute myeloid leukemia, acute lymphocytic leukemia, or lymphoma, with choices made by their healthcare providers based on institutional practices. No study medication is provided by the sponsor. The study collects data retrospectively without administering new treatments. During the study, researchers collect information on response rates, duration of response, progression-free and overall survival, adverse events, transfusion needs, treatment durations, hospitalization details, and transitions to stem cell transplant. Data is gathered from the start of treatment through up to 26 months, offering insights into treatment patterns and outcomes. Participants privacy and consent are managed following local regulations.
Actively Recruiting
Researchers are evaluating Enzomenib DSP-5336, an oral drug, in patients with various types of acute leukemia, including relapsed or refractory acute myeloid leukemia AML, acute lymphocytic leukemia ALL, and acute leukemia of ambiguous lineage. The study also includes patients with high-risk myelodysplastic syndromes MDS and relapsed multiple myeloma MM in selected sites. This phase 12 trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of DSP-5336 alone or combined with standard AML treatments, particularly in patients with specific genetic mutations like MLL rearrangement or NPM1 mutation. The study involves dose escalation and dose expansion of DSP-5336 administered orally. Participants may receive DSP-5336 alone or combined with standard AML regimens such as venetoclax plus azacitidine or intensive chemotherapy with cytarabine and daunorubicin 73. Different study arms include patients with or without certain medications like CYP3A4 inhibitor azoles, and those with specific genetic profiles. The trial evaluates recommended phase 2 doses for various patient groups and combination treatments. Participants will undergo assessments including monitoring for adverse events within 30 days after the last dose and evaluation of clinical responses approximately six months after treatment begins. Researchers will collect blood and bone marrow samples for genomic analysis and track drug levels in the body. Safety labs, ECGs, physical exams, and patient questionnaires will be performed throughout the study. The trial includes long-term follow-up of overall survival up to two years after treatment ends, with visits and tests scheduled to monitor health and treatment effects.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness of JNJ-79635322 compared to teclistamab in adults with relapsed or refractory multiple myeloma who have received 1 to 3 prior treatments, including an anti-CD38 antibody and lenalidomide. This phase 3 randomized study aims to assess how well these treatments work in controlling the disease and improving patient outcomes. Participants will receive subcutaneous injections of either JNJ-79635322 for a limited time or until intolerable side effects occur, or teclistamab as a subcutaneous injection until disease progression or intolerable toxicity. The study compares these two treatment approaches in parallel groups to observe differences in clinical response and safety. During the study, participants will be regularly monitored with laboratory tests and evaluations to measure responses such as complete response, progression-free survival, and quality of life. Researchers will track side effects, symptoms, and functioning over up to approximately 41 months. The study includes detailed assessments using questionnaires and laboratory parameters to understand treatment impact and safety throughout the participation period.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating alisertib combined with endocrine therapy in adults with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed after at least two prior endocrine treatments. This phase 2 study aims to find the best alisertib dose when used with endocrine therapy and to assess the treatments effectiveness, safety, and how the body processes the drug. The study also seeks to identify specific biomarker groups that may benefit most from the combination therapy. Participants receive alisertib tablets taken orally twice daily on days 1-3, 8-10, and 15-17 in each 28-day cycle along with a chosen endocrine therapy such as anastrozole, letrozole, exemestane, tamoxifen, or fulvestrant following approved dosing schedules. Participants were randomized to different dose groups of alisertib combined with endocrine therapy, with some groups closed to new enrollment after protocol updates. Treatment continues with regular cycles as per the study design. Throughout the study, participants undergo evaluations including tumor response measurements, duration and control of disease, progression-free and overall survival tracked up to 48 months. Safety is monitored by recording adverse events from the first dose through 28 days after the last dose. Researchers also collect pharmacokinetic data and biomarker information to understand treatment effects. The total participation duration aligns with the treatment cycles and follow-up assessments scheduled over several years.
Actively Recruiting
Researchers are evaluating ARC-02 for adults with B-cell Non-Hodgkin Lymphoma NHL, including various types such as follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. This Phase 1 study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early effectiveness of ARC-02 in participants who have previously received at least two lines of systemic therapies and have disease requiring treatment. Participants will receive ARC-02 through intravenous infusion on Day 1 of each cycle until their disease worsens or unacceptable side effects occur. The study includes multiple dose levels of ARC-02 alone or combined with rituximab, with dosing determined during dose escalation phases. There are four groups ARC-02 monotherapy dose escalation, ARC-02 monotherapy dose expansion, ARC-02 combined with rituximab dose escalation, and ARC-02 combined with rituximab dose expansion. During the study, participants will be monitored for dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events over a period of up to five years. Researchers will evaluate response rates, time to response, duration of response, progression-free survival, and various pharmacokinetic measures. Participants will have regular assessments to track safety and clinical activity throughout the treatment and follow-up period, which may last several years.
Actively Recruiting
Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.
1-10 of 59
1